Cell BioEngines Revenue and Competitors

About Us:\nCell BioEngines, Inc., founded in Dec 2022, is a clinical-stage biotech company focused on developing allogeneic 'off-the-shelf' stem cell and its derived therapies as ‘drugs’ for human disease treatment.\n\nThe company utilizes a ‘plug-and-play’ proprietary platform technology that transforms universal ‘non-gene-modified’ donor blood stem cells from umbilical cords, to produce high-quality, pure and potent, multiple clinical grade cells at scale. This innovative method aims to make stem cells and its derived therapies more accessible and efficient.\n\nIts lead product is currently in Phase 1 trials for the treatment of hematopoetiic neoplasms not curable with available therapies, particularly acute leukemia and myelodysplasia. The lead pre-clinical stage product is a first-in- class ‘one-size-fits-all’ cell-based cancer vaccine, composed of dendritic cell type 1 (cDC1) to circumvent the barriers in solid cancers.\n\nPlatform Technology:\nThe company's platform technology is what makes it innovative and unique. It's \Cell BioEngineMAP\ is a cutting-edge platform for developing multiple cell therapy assets, leveraging the remarkable potential of universal umbilical cord-derived blood stem cells. These cells serve as a foundational source, which can expanded, differentiated, and de-differentiated using proprietary chemical reprogramming methods to produce pure, powerful rare cell states, at large scale for clinical applications.\n\nComplementing this, company's \Cell BioEngineAI\ platform employs artificial intelligence to predict donor availability and target characteristics, ensuring the safety and efficacy of HLA-compatible therapies. The goal is to create a ready-to-use, 'off-the-shelf' cell bank with therapeutic products that cover over 85% of the population, available at selected blood centers. \n\nFor more information, visit www.cellbioengines.com and follow us on www.twitter.com/cell_bioengines